🇦🇺 Australia Country × Condition
breast cancer Clinical Trials in Australia
Active clinical trials for breast cancer with research sites in Australia. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 11 // Recruiting: 11 Phases: Phase 3, Phase 1 // Updated: Daily
Total Trials
11
Recruiting Now
11
Country
🇦🇺 Australia
Active Trials in Australia (11)
NCT06982521 Phase 3
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Enrollment
540 pts
Country
🇦🇺 Australia
Relay Therapeutics, Inc.
View Trial → NCT07358377 Phase 1
Recruiting
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
Enrollment
15 pts
Country
🇦🇺 Australia
Atridia Pty Ltd.
View Trial → NCT05735080 Phase 1, Phase 2
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Enrollment
150 pts
Country
🇦🇺 Australia
Incyclix Bio
View Trial → NCT05872295 Phase 1
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
Enrollment
165 pts
Country
🇦🇺 Australia
Iksuda Therapeutics Ltd.
View Trial → NCT07085767 Phase 3
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Enrollment
1,000 pts
Country
🇦🇺 Australia
Olema Pharmaceuticals, Inc.
View Trial → NCT05508906 Phase 1
Recruiting
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Enrollment
190 pts
Country
🇦🇺 Australia
Olema Pharmaceuticals, Inc.
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇦🇺 Australia
PMV Pharmaceuticals, Inc
View Trial → NCT07661641 Phase 1
Recruiting
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
Enrollment
115 pts
Country
🇦🇺 Australia
Alpha-9 Oncology USA Inc.
View Trial → NCT05307705 Phase 1
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Enrollment
260 pts
Country
🇦🇺 Australia
Eli Lilly and Company
View Trial → NCT06401304
Recruiting
Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)
Enrollment
1,200 pts
Country
🇦🇺 Australia
Uppsala University
View Trial → NCT06492616 Phase 3
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Enrollment
4,220 pts
Country
🇦🇺 Australia
Stemline Therapeutics, Inc.
View Trial → Frequently Asked Questions
How many breast cancer clinical trials are active in Australia?
There are currently 11 active clinical trials for breast cancer with sites in Australia, of which 11 are actively recruiting patients.
How can I join a breast cancer clinical trial in Australia?
To join a breast cancer clinical trial in Australia, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Australia directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are breast cancer trials in Australia?
Active breast cancer trials in Australia span Phase 3, Phase 1, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology